Caregiver burden and quality of life in late stage Parkinson’s disease
Objective: To describe and assess factors associated with informal caregiver quality of life (QoL) in late stage Parkinson’s disease (PD). Background: In the late stage…The effects of converting to Dysport from other botulinum toxin type A formulations for treating cervical dystonia patients
Objective: To investigate whether Dysport increases waning time compared to other botulinum toxin type A (BoNT-A) formulations for cervical dystonia (CD) therapy. Background: BoNT-A injections…Dysphagia and its relationship to medication intake in Parkinson’s disease
Objective: This study attempted to obtain a comprehensive picture of medication intake dysphagia in Parkinson’s disease (PD). Specific investigations included 1) An objective, graduated and…DystoniaBoTXNet: A Deep Learning Platform for Predictive Outcome of Botulinum Toxin Treatment in Isolated Dystonia
Objective: To develop and validate an objective measure of the botulinum toxin treatment outcome in isolated dystonia. Background: Dystonia is characterized by abnormal, often painful,…Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.
Objective: To compare the duration of continuous “On” without troublesome dyskinesia (“Good On”) intervals and number of motor fluctuations per day in Parkinson’s disease (PD)…Characterization of nociplastic pains in Parkinson’s disease (PD) with the PD pain classification system (PD-PCS)
Objective: To describe the new category of nociplastic pain (NP). We defined Parkinson's disease (PD)-related pains and allocated them to a mechanistic category by using the…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.